![](/img/cover-not-exists.png)
Patients with primary immunodeficiency receiving subcutaneous immune globulin Hizentra maintain health-related quality of life and treatment satisfaction in a multicentre extension study of efficacy, tolerability and safety
Christopher A. Jones, Mikhail Rojavin, Jeffrey S. BaggishVolume:
3
Year:
2012
Language:
english
DOI:
10.1111/j.1759-8893.2011.00076.x
File:
PDF, 500 KB
english, 2012